Who we are
Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for cell and gene therapy viral vector manufacturing.
As a trusted partner for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 sq ft. (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substance (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 sq ft. (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance.
Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high quality gene-modified cell therapies and in vivo gene therapy projects.
Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

Bioprocess development (USP & DSP)
We use innovation to reach new heights in production efficiency.
Discover
cGMP manufacturing of clinical and commercial viral vector batches
Our extensive AAV and lentiviral vector manufacturing capacity helps ensure on-time deliver.
Learn more
Analytical development, assays qualification & validation
Our experts aim to satisfy all your analytical needs with high quality.
Discover
Fill & Finish
We offer a variety of cGMP compliant vials filling format for Fill & Finish.
Learn morePartnering to bring your Cell and Gene therapies to life...

Growing Capacity
Time is of essence in the clinical development of new therapies, and manufacturing is often a real bottleneck for cell and gene therapy products. At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Our growing cGMP facilities, dedicated manpower, and expertise allow us to easily accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments.

Trusted partner
Yposkesi is a trusted partner with both technical expertise and a long-term commitment to quality.
Our services encompass process development, cGMP manufacturing of AAV and lentiviral vectors, Fill & Finish, QC, QA, and regulatory support. We aim to establish an open and trustworthy relationship with you with the ultimate goal of reducing time-to-market and ensuring an uninterrupted supply of viral vectors.

Innovation
There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products.
As a leading CDMO, Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable, and competitive AAV and lentiviral vector supply.
Our News, Blog & Events
News

Yposkesi reinforces team with three executive appointments
12 July 2022
Yposkesi appoints US-based Executive Director for Business Development
1 March 2022
ASMA Consortium: Improving access to innovative bio therapeutics through acoustic technologies
22 February 2022Blog

Bioprocess Development: A Complete Overview
25 January 2023
Advanced – But Not Advanced Enough
21 December 2022
What is a CDMO? A guide for Business
24 November 2022Events

Meet our team at IO360°: Feb. 7-10, 2023 in New-York, NY.
23 January 2023
Meet our team at Phacilitate Advanced Therapies Week US: Jan. 17-20, 2023 in Miami, FL.
2 December 2022